General Information of Drug (ID: DMPC2QY)

Drug Name
CNTO-1959 Drug Info
Synonyms Guselkumab
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Approved [1]
Asthma CA23 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMPC2QY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-23 (IL23)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ustekinumab DMHTYK3 Plaque psoriasis EA90.0 Approved [4]
Tildrakizumab DMLW9HG Plaque psoriasis EA90.0 Approved [5]
Risankizumab DMM32GT Plaque psoriasis EA90.0 Approved [6]
BI 655066 DMBH4FL Chronic plaque psoriasis EA90.0 Phase 3 [7]
MK-3222 DMQBF7O Hairy cell leukaemia 2A82.2 Phase 3 [8]
Brazikumab DM4NWPE Crohn disease DD70 Phase 3 [9]
ABP 654 DM0GXWT Plaque psoriasis EA90.0 Phase 3 [10]
CNT0-1959 DMOR8SY Rheumatoid arthritis FA20 Phase 2 [3]
mRNA-2752 DMUKBI2 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
AMG-139 DMEHOVF Crohn disease DD70 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Not Available [3]

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7998).
3 Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
4 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
7 Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
8 Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
9 Blockade of IL-23: What is in the Pipeline? J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72.
10 Clinical pipeline report, company report or official report of Amgen
11 Clinical pipeline report, company report or official report of Moderna Therapeutics.
12 Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.